ChiCTR2600127270 Trastuzumab Rezetecan Solid tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines ChiCTR2600127270 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 4 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why ChiCTR2600127270 is a hot trial to watch
Solid tumor is being segmented by mechanism, treatment setting, geography and endpoint architecture. ChiCTR2600127270 is notable because it evaluates Trastuzumab Rezetecan in a Phase 1/2 design sponsored by Zhejiang Cancer Hospital. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | ChiCTR2600127270 |
| Official title | Trastuzumab Rezetecan or Irinotecan Liposome (II) Combined with Anlotinib in the Treatment of Patients with Relapsed or Metastatic Small Round Cell Sarcoma and Other HER2-Abnormal Solid Tumors: A Prospective, Multi-Cohort, Phase Ib/II Clinical Study |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | Trastuzumab Rezetecan |
| Sponsor | Zhejiang Cancer Hospital |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | Objective response rate, ORR |
| Endpoint time frame | Evaluate every two cycles after starting treatment, regardless of whether the medication is delayed. |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1/2 study of Trastuzumab Rezetecan in Solid tumor.
Allocation is Non-Randomized, masking is NA, and the intervention model is not reported. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Objective response rate, ORR (Evaluate every two cycles after starting treatment, regardless of whether the medication is delayed.) — Imaging examinations of the chest, abdomen, and pelvis are required. The abdomen and pelvis need enhanced MRI/enhanced CT scans (scan slice thickness ≤ 5 mm), and the chest requires a CT scan (scan slice thickness ≤ 5 mm). If brain metastasis is suspected, enhanced MRI/enhanced CT of the brain is also needed to rule out brain metastasis. When bone metastasis is confirmed or clinically suspected, a bone scan is requir
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Trastuzumab Rezetecan is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Zhejiang Cancer Hospital is resolved to a normalized organization record in Hangzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
ChiCTR2600127270 provides a focused lens on Solid tumor development. Its value will be determined by whether Trastuzumab Rezetecan can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
